Researchers from the Francis Crick Institute and the Latvian Institute of Organic Synthesis developed a new compound that blocks a step in the life cycle of the mosquito-borne parasite that causes malaria.
Artios Pharma entered into a global research collaboration with Novartis for the purpose of discovering and validating next-generation DNA damage response (DDR) targets and enhancing Novartis’ radioligand therapies.
GlaxoSmithKline opened a new $13 million research hub in London focused on artificial intelligence.
Working with a new class of drugs called G12C KRAS inhibitors, the Francis Crick Institute and Institute of Cancer Research developed product combos to stay ahead of drug-resistant tumors.
